Why is India’s obesity drug market thinning despite the GLP-1 rush?

Business Today

Why is India’s obesity drug market thinning despite the GLP-1 rush?

Generic semaglutide launches have expanded access and pushed India's GLP-1 market close to Rs 2,000 crore. But as the initial rush fades, companies face a tougher challenge of finding new obesity patients and keeping them on treatment.

Go to News Site

Google Play

App Store